NRX Pharmaceuticals Reports Director/Officer Changes & Financials
Ticker: NRXPW · Form: 8-K · Filed: Jun 20, 2024 · CIK: 1719406
| Field | Detail |
|---|---|
| Company | Nrx Pharmaceuticals, INC. (NRXPW) |
| Form Type | 8-K |
| Filed Date | Jun 20, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, director-changes, financials
Related Tickers: NRXP
TL;DR
NRXP board shakeup and financials filed - watch for strategic shifts.
AI Summary
NRX Pharmaceuticals, Inc. filed an 8-K on June 20, 2024, reporting changes effective June 13, 2024. The filing pertains to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. It also includes financial statements and exhibits.
Why It Matters
Changes in a company's board of directors and executive officers can signal shifts in strategy or governance, while the inclusion of financial statements provides insight into the company's financial health.
Risk Assessment
Risk Level: medium — Changes in directors and officers, coupled with financial reporting, can indicate significant internal shifts that may impact future performance.
Key Players & Entities
- NRX Pharmaceuticals, Inc. (company) — Registrant
- Big Rock Partners Acquisition Corp. (company) — Former Company Name
- June 13, 2024 (date) — Effective date of events reported
- June 20, 2024 (date) — Filing date of the 8-K
FAQ
What specific changes occurred regarding directors or officers?
The filing indicates the departure of directors or certain officers, the election of directors, and the appointment of certain officers, effective June 13, 2024.
What are the key items reported in this 8-K filing?
The filing covers the departure/election/appointment of directors and officers, compensatory arrangements, and financial statements and exhibits.
When was this 8-K report filed with the SEC?
This 8-K report was filed on June 20, 2024.
What was NRX Pharmaceuticals, Inc. formerly known as?
NRX Pharmaceuticals, Inc. was formerly known as Big Rock Partners Acquisition Corp.
What is the state of incorporation for NRX Pharmaceuticals, Inc.?
NRX Pharmaceuticals, Inc. is incorporated in Delaware.
Filing Stats: 832 words · 3 min read · ~3 pages · Grade level 12 · Accepted 2024-06-20 17:03:57
Key Financial Figures
- $0.001 — registered Common Stock, par value $0.001 per share NRXP The Nasdaq Stock Mar
Filing Documents
- nrxp-20240613x8k.htm (8-K) — 46KB
- nrxp-20240613xex99d1.htm (EX-99.1) — 13KB
- 0001558370-24-009369.txt ( ) — 222KB
- nrxp-20240613.xsd (EX-101.SCH) — 4KB
- nrxp-20240613_def.xml (EX-101.DEF) — 14KB
- nrxp-20240613_lab.xml (EX-101.LAB) — 20KB
- nrxp-20240613_pre.xml (EX-101.PRE) — 15KB
- nrxp-20240613x8k_htm.xml (XML) — 7KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 13, 2024, NRx Pharmaceuticals, Inc. (the " Company ") appointed Dr. Dennis McBride to serve as a member of the Board of Directors of the Company. Dennis McBride, Ph.D., age 70, serves as a research professor at Virginia Tech since May 2021, and has led numerous national and international initiatives in neuroscience and its interface with information technology, national security, and medical technology/drug development within the federal government, three of which are now multi-billion dollar enterprises. Dr. McBride also served as Director of the Acquisition and Innovation Research Center for the Department of Defense from February 2022 to February 2024, and as Vice President of Strategy and Innovation at Source America from December 2015 - December 2020. Dr. McBride began his career as a medical scientist in Naval Aviation and ergonomics and served in eight nationally prominent laboratories, including the Defense Advanced Research Projects Agency (DARPA), Naval Aerospace Medical Research Lab, Naval Research Lab, the Office of Naval Research, and the Naval Medical Research Institute. Upon retiring as a highly decorated senior officer (O-6), he assumed leadership of the Potomac Institute for Policy Studies, where he continues to serve as President Emeritus. Following his ten-year term, he was recruited back to the National Defense University to lead the Center for Technology and National Security Policy, culminating his government career as a Senior Executive-4 (Civilian equivalent to Rear Admiral/Vice Admiral). Dr. McBride has served as an adviser to Cabinet Secretaries, US Congressional Committees, and to corporate C-Suite executives. His educational background includes formal enrollment at the University of Georgia, Naval Aerospace Medical Institute (flight surgeon school), the University of Sout
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by NRx Pharmaceuticals, Inc., dated June 18, 2024 104 Cover Page Interactive Data File (formatted as Inline XBRL).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NRX PHARMACEUTICALS, INC. Date: June 20, 2024 By: /s/ Stephen Willard Name: Stephen Willard Title: Chief Executive Officer